3:10 PM
 | 
Jun 04, 2018
 |  BC Extra  |  Clinical News

Kite reports data for TCR therapy in HPV-positive solid tumors

The Kite Pharma Inc. subsidiary of Gilead Sciences Inc. (NASDAQ:GILD) reported data from seven evaluable patients with metastatic HPV-16-positive solid tumors in the NCI-sponsored Phase I 16-C-0154 trial showing that a single infusion of a TCR cell therapy targeting E7 transforming protein (HPV-16; HpV16gp2) led to three partial responses and two cases of stable disease.

Kite said...

Read the full 263 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >